Skip to main content
David O'Malley, MD, Obstetrics & Gynecology, Hilliard, OH, The OSUCCC - James

DavidMO'MalleyMD

Obstetrics & Gynecology Hilliard, OH

Gynecologic Oncology

Professor of Obstetrics & Gynecology The Ohio State University and James CCC; Director, Clinical Research Gynecologic Oncology; ORIEN Physician Liaison for OSUCCC-James

Dr. O'Malley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. O'Malley's full profile

Already have an account?

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Gynecologic Oncology, 2002 - 2005
  • The MetroHealth System/Case Western Reserve University
    The MetroHealth System/Case Western Reserve UniversityResidency, Obstetrics and Gynecology, 1998 - 2002
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Obstetrics and Gynecology, 1998 - 2002
  • Wayne State University School of Medicine
    Wayne State University School of MedicineClass of 1998
  • University of Notre Dame
    University of Notre DameBA, Pre-Med, 1989 - 1992

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2005 - 2024
  • CT State Medical License
    CT State Medical License 2002 - 2006
  • American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase Ib Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Pl...  
    David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lainie P Martin, Kathleen N Moore, Gynecologic Oncology

Lectures

  • Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resi... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Mirvetuximab soravtansine, a folate receptor alpha (FR±)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resis... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • David O'Malley, MD, on Dual Immunotherapy for Advanced Cervical Cancer
    David O'Malley, MD, on Dual Immunotherapy for Advanced Cervical CancerMarch 9th, 2022
  • ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin
    ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with AvastinMay 15th, 2019
  • ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin
    ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with AvastinMay 16th, 2018

Professional Memberships

Hospital Affiliations